The premenstrual syndrome (PMS) has been proposed to result from excessive exposure to and/or withdrawal of brain opioid activity during the luteal phase. Because hypothalamic opioids are believed to modulate GnRH secretion, in part under the influence of ovarian steroids, we performed longitudinal studies of gonadotropin and ovarian steroid secretion across ovulatory, symptomatic cycles of 17 PMS patients and 8 normal volunteers. Pulsatile LH secretion was measured every 10 min for 8 hr at times when central opioid activity was expected to be low (early follicular phase), high (mid-luteal phase; ML), and declining (late luteal phase). In both subject groups, a cycle-phase effect was observed for LH pulse frequency (p =<0.001) and amplitude (p =0.002), and for the transverse mean concentrations of LH (p =0.05), FSH (p <= 0.001), estradiol (E2) (p=<0.001) and progesterone (P) (p =<0.001). ML P secretion in PMS patients was pulsatile, and mean concentrations (over 30-60 min) were similar to those of normal controls. The changes in pulsatile LH secretion across the cycle were not different in the PMS patients compared to the normal women, though mean FSH in the ML phase was higher in the PMS group (p =<0.05). The similar changes in luteal LH pulse frequency fail to provide evidence that GnRH secretion is impaired, thus challenging the view that the neuroregulation of the menstrual cycle in women with PMS is markedly altered.
INTRODUCTION
THE MECHANISMS INVOLVED in producing the complex of symptoms collectively termed the premenstrual syndrome (PMS) are unknown. The failure to identify gross aberrations in plasma concentrations of the reproductive hormones has led investigators to search for a common link between the dynamic neuroendocrine secretory events that characterize the menstrual cycle and central mechanisms regulating behavior and mood states. It has been proposed that premenstrual symptoms occur in response to the cyclic rise and fall in hypothalamic opioid activity believed to modulate the pulsatile release of gonadotropin-releasing hormone (GnRH) and, in turn, luteinizing hormone (LH), as a result of the characteristic changes in the ovarian production of estrogen and progesterone (P) (Halbreich & Endicott, 1981; Reid & Yen, 1981) . Advocates propose that the withdrawal of high opioid activity prior to menses disinhibits opioid-sensitive neurons, resulting in such dysphoric symptoms as irritability, insomnia, food cravings, anxiety, and pain sensitivity (Chuong et al., 1988; Facchinetti et al., 1988; 1990) . LH pulse frequency in the mid-luteal (ML) phase has been reported to be faster in PMS patients, despite similar concentrations of P compared to normal volunteers (Facchinetti et al., 1990 ). This finding, as well as earlier evidence that LH responsiveness to the opiate antagonist, naloxone, was blunted in PMS patients (Facchinetti et al., 1988) , prompted these investigators to propose that PMS was a central disorder, due to a hypothalamic impairment of the opioid inhibition normally present at this time in the cycle. Differences in LH pulse frequency and amplitude between the patient and control groups in the later study (Facchinetti et al., 1990) were small, however, and secretory characteristics were within the normal range of variability previously reported for normal, asymptomatic women (Reame et al., 1984) . In addition, these investigators noted that the presence of secondary psychiatric disorders in some of the PMS subjects may have confounded their results.
Given the recognized role of endogenous opioids in mediating the luteal slowing of GnRH/LH pulsatile secretion (Quigley & Yen, 1980; van Vugt et al., 1984) , and to further characterize the neuroreproductive axis in PMS, we conducted a longitudinal assessment of pulsatile gonadotropin and ovarian steroid secretion in women with PMS at times in the menstrual cycle previously shown to be differentially influenced by central opioid activity (Quigley & Yen, 1980; Wardlaw et al., 1982) .
SUBJECTS AND METHODS

Subjects
Twenty women between the ages of 26 and 39 yr (mean + SEM = 32.9 + 4 yr) were recruited from a pool of 172 gynecologic patients diagnosed with PMS as defined by the National Institute of Mental Health guidelines (Blume, 1983) . Subjects were referred by their clinician after symptom assessment but prior to the initiation of therapy. The diagnosis of PMS was based on prospective confirmation of the presence of luteal phase emotional and physical symptoms which resolved before the end of menses and occurred in at least two subsequent cycles. The symptom rating scales used by the referring physicians included the Self Rating Scale for Premenstrual Tension Syndrome , the Prospective Record of the Impact and Severity of Menstrual Symptomatology (PRISM) calendar (Reid, 1985) , and a visual linear analogue scale (Casper & Powell, 1986) .
Selection criteria included a history of regular menses, normal body weight (+15% ideal body weight [IBW]) and 6 mo or more of cyclic distress resulting in significant disruption of personal or professional functioning. The mean duration of PMS symptoms was 5.2+0.4 yr (range 3-9 yr). All subjects were free of demonstrable medical illness and had not been taking medications, including oral contraceptives, during the previous 6 mo. There was no evidence of psychiatric dysfunction as measured by the SCL-90 Questionnaire (Derogatis et al., 1976) , the Center for Epidemiologic Studies Depression Scale (Radloff, 1977) , or psychiatric interview conducted during the follicular phase of the cycle. There was no hirsutism or clinical evidence of thyroid disease on physical examination, and plasma prolactin, testosterone, dihydroepiandrosterone sulphate, and beta human chorionic gonadotropin were normal at the time of study.
Protocol
The studies were approved by the Institutional Review Board and were performed in the Clinical Research Center of the University of Michigan Hospital after written informed consent had been obtained.
LH pulsatility was assessed longitudinally at three time points in the menstrual cycle which have been previously well-characterized in normal women, and when endogenous opioid activity is presumed to be minimal (early follicular phase; EF), maximal ML phase and diminished (late luteal phase; LL). Studies were conducted on days 5-6 after menses onset (EF), days 5-9 post-LH surge (ML), and days 11-15 post-LH surge (LL). In all cases, the ML and LL studies were at least 5 days apart. During each 8-hr study (0900h-1700h), blood samples were obtained through an indwelling intravenous forearm catheter every 10 min for measurement of LH, every 60 min for FSH, every 30 min for P in the ML and 60 min in the LL, and every 2 hr for estradiol (F_~.) . The timing of the LH surge was estimated by the increase in urinary LH determined with a home, enzyme-linked immunosorbent assay kit (First Response TM, Tambrands, Lake Success, NY). Blood also was obtained for determination of F_~ and P every other day between the ML and LL study days.
Symptom Assessment
To confirm menstrual symptom characteristics during the study cycle, subjects rated themselves on the incidence and severity of 40 symptoms commonly associated with menstrual cycle distress using a check list developed by Woods (1987) , based on the work of Moos (1968) , Haskett et al. (1980) , and Halbreich et al. (1982) . Beginning 2 wk prior to the onset of the study cycle, women rated the items on a scale of 0 (not present) to 4 (extreme) at the end of each day. The 40 menstrual-related items were embedded alphabetically within a larger list of 57 negative and positive symptoms (e.g., blurred vision, general well-being). After data collection, the daily diaries were synchronized with menstrual cycle days. The three highest daily symptom scores of the postmenstrual week (days 4 through 10 after menses onset) and the subsequent premenstrual week (days 7 through 1 premenses) were used to compute a menstrual phase mean score (Woods, 1987) .
Control Studies in Normal Volunteers
Eight normal volunteers prospectively monitored body symptoms across a menstrual cycle during which blood-sampling studies were performed in the EF and ML. In four subjects, a third study was conducted in the LL. Criteria for subject selection included: 21-39 yr of age, regular cycles of 25-32 days, normal body weight (+ 15% IBW), postpartum and nonlactating for at least 6 mo, no medication use including oral contraceptives for the previous 6 mo, no history of medical treatment for endocrine or gynecologic disease including debilitating premenstrual/menstrual complaints, and normal findings on physical examination.
Assays
Plasma LH and FSH were measured by (RIA) methods previously reported (Midgley, 1966; 1967) . Plasma F a (assay sensitivity: 5 pg/ml, 18 pmol/l) and P (assay sensitivity: 0.2 ng/ml, 0.64 nmol/1) were measured with RIA kits (Diagnostic Products, Los Angeles, CA; Radioassay Systems Laboratories, Carson, CA). Gonadotropin concentrations are reported as IU/1 of the second IRP human menopausal gonadotropin after conversion from LER 907, which was used as the assay standard. For the LH and FSH assays, the assay sensitivities were 1.0 and 1.4 IU/I, respectively, and the interassay coefficient of variation (CV) was 11%. For LH and FSH, the intraassay CV was inversely proportional to the measured amount, averaging 20%, 9.5% and 6.6% for concentrations of 2.5, 7.5 and 15 IU/1, respectively. For analysis, values below assay sensitivity were assigned a value of the assay sensitivity.
LH Pulse Analysis
The number of LH pulses occurring in each 8-hr sampling period was determined as previously described (Reame et al., 1984; Hale et al., 1988) . A minimal detectable increment (MDI) was determined for each 8-hr sampling period. The MDI was calculated as the product of the mean LH concentration and three times the intraassay coefficient of variation (CV) of replicate samples for each sampling period (MDI = mean LH × CV x 3). If the calculated MDI was less than the assay sensitivity for that period, the value of the assay sensitivity was used. An LH pulse was defined as an increase from nadir to peak greater than or equal to the MDI, occurring within 40 min. The LH pulse amplitude was calculated as the difference between the peak value and the preceding nadir value. Only those pulses with amplitudes exceeding the mean assay sensitivity (1.0 IU/1) were accepted. The maximum false positive rate was less than 1-2 pulses/100 comparisons. Missing values comprised less than 0.5% of the total samples and were left blank. This method of pulse analysis has been compared in previous studies of normal women to the computerized peak detection program, Detect, version 4.8 (Oerter et al., 1986) , and shown to provide similar estimates of pulse frequency (Nippoldt et al., 1989) .
Statistical Analysis
Data are presented as means +SEM. Hormone values are expressed as IU/1 for LH and FSH, nmol/1 for P, and pmol/l for E 2 (1 ng= 3.18 nmol; 1 pg = 3.6 pmol). The distribution of hormone values was assessed for normality. In some cases, a log transformation was needed due to skewed distribution; however, transformation did not change any of the results, and the transformed data axe not reported. Differences in mean hormone secretion characteristics across the three cycle phases in the patient and control groups were determined by analysis of variance and multiple comparison procedures (Fisher's least significant difference or Sheffe) if the overall F ratio was significant (p =< 0.05).
RESULTS
Menstrual Cycle Characteristics
Study cycles from all subjects were judged to be ovulatory as evidenced by plasma P values of > 15 nmol/1 (5 ng/ml) on at least two occasions in the ML phase. In three subjects in the PMS group, peak plasma P levels were not observed until 11 to 14 days after the estimated LH surge, and cycle lengths were 22, 37 and 40 days. Post-study cycles were 26, 28 and 25 days in length, respectively. Because these observations suggested atypical ovulatory cycles, the data from these individuals were excluded from analysis, resulting in a final sample size of 17 in the PMS group. None of the normal volunteers experienced an atypical cycle during the study, although it has been our experience over the last 10 yr that abnormal cycles occur in approximately 10% of subjects who undergo these intensive studies.
Symptom Characteristics During Study
In both the postmenstrual and the premenstrual weeks of the study cycle, the volunteer group demonstrated a lower mean symptom score (p = 0.001, ANOVA) than the patient group. Mean age and cycle length were similar (Table I) . Since underlying psychiatric disorders had been ruled out during the diagnostic evaluation, the higher "baseline" scores of the postmenstrual week more likely reflected the chronic nature and severity of the menstrual health problem. Little is known about how PMS symptom patterns change over time, especially in women who fail to benefit from standard treatment approaches. It has been proposed that for women suffering from severe, long-term premenstrual symptoms, the "symptom-free" interval associated with the follicular phase is compromised by feelings of guilt and depression for neglect of family and professional responsibilities (Reid, 1985) .
The PMS group showed an almost three-fold increase in mean symptom scores in the subsequent premenstrual week (57.9+ 6) compared to postmenstrual values (19.8 + 4.0; p =0.001, ANOVA). The scores of most PMS subjects greatly exceeded the minimum 30% increase (% mean increase+SEM=525+ 181%; range=36% to 2250%) required to meet the definition for PMS adopted by the National Institutes of Mental Health PMS Research Workshop Workgroup (Blume, 1983) . 
TABLE I. CLINICAL CHARACTERISTICS AND MENSTRUAL SYMPTOM SCORES (MEAN-----SEM) AT THE TIME OF STUDY FOR PMS PATIENTS AND NORMAL VOLUNTEERS (NV)
Gonadotropin and Ovarian Steroid Secretion in PMS Patients
By ANOVA, a significant luteal phase change occurred in mean LH concentration, LH pulse frequency, LH pulse amplitude, mean FSH, and mean levels of F_. 2 and P (Table ID. LH pulse frequency slowed from an EF frequency of 7.5+ 0.6 pulses/8 hr to 4.0+0.3 pulses/8 hr in the ML, and pulse amplitude increased from 2.2+ 0.2 IU/1 (EF) to 4.6+0.7 IU/1 (ML). Mean FSH was lower in the ML when ovarian steroids were elevated. Figure 1 presents serial measures of plasma gonadotropins and ovarian steroids in two subjects with PMS showing representative changes in pulsatile LH secretion between the follicular and luteal studies.
During the ML studies, plasma P was measured every 30 min and assessed for pulsatile secretion. By criteria previously used in normal women (a secretory pulse was defined as an increase of five times the SEM of the mean within 120 min of the previous nadir [Healy et al., 1984] ), secretory fluctuations of 12.7+2.0 nmol/1 (4.0+ 0.7 ng/ml) amplitude occurred at a mean frequency of 2.4 + 0.4 pulses/8 hr. Figure 2 shows ML P secretion in three subjects with varying severity of PMS symptoms. During the ML studies, plasma P was close to the group mean level (30.9+ 4.0 nmol/1; 9.5+1 ng/ml) in PMS subjects with both high (Subject 5) and low (Subject 6) symptom severity scores. In Subject 2, low symptom severity scores were associated with plasma P levels in the high-normal range, but LH pulse frequency was not excessively slowed in this individual (5 pulses/8 hr). Overall, there was no significant correlation between MLP concentrations and premenstrual symptom scores.
Comparison of Data in PMS Subjects and Normal Volunteers
Plasma ovarian steroids were not statistically different between groups on the three study days, although in the LL, a lower mean value for both E 2 and P in the normal volunteers was apparent. The four normal volunteers were all evaluated on the day prior to menses, resulting 
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. in lower values compared to the PMS group, in whom LL studies were performed on average 2 days prior to menses. Single measures of E 2 and P taken between the ML and LL studies (days 9 and 11 post-LH surge) revealed no difference in the rate of decline in corpus luteum function for the two groups. Mean plasma FSH was different in the PMS and control groups (p = 0.002; ANOVA), in that mean FSH was higher in the PMS patients in the ML studies (p =<0.05, Fisher's multiple comparison) . No significant differences in pulsatile LH secretory characteristics were found between PMS patients and normal volunteers across the three study days.
DISCUSSION
We studied changes in pulsatile LH secretion in women with PMS to detect peripheral evidence of alterations in the transient increase and withdrawal of endogenous opioid action on GnRH secretion during ovulatory, symptomatic cycles. We chose three different "windows" in the menstrual cycle which have been characterized previously in relation to ovarian steroids, gonadotropin secretion, menstrual symptomatology, and presumed opioid activity. The current view of the hormonal interrelationships in the normal luteal phase is that P in the presence of E 2 acts on the hypothalamus to transiently increase opioid activity, thus inhibiting the frequency of pulsatile GnRH secretion and in turn the pulsatile release of LH (Yen et al., 1972; Backstrom et al., 1982; Filicori et al., 1984; Soules et al., 1984) . With the fall in E 2 and P secretion from the aging corpus luteum, opioid exposure is withdrawn, allowing GnRH pulsatile secretion to increase in the days preceding menses (Marshall & Kelch, 1986) . Thus, assessment of LH pulse frequency in women has been used to infer changes in GnRH secretion and may allow a gross estimation of hypothalamic opioid influence when performed in the presence of a welldefined ovarian steroid milieu.
A more direct measure of hypothalamic opioid activity is LH responsiveness to naloxone infusion, which was not assessed in the present study. We chose to characterize the phasic changes in endogenous pulsatile LH secretion without the potential effects of an agent known to influence LH pulse characteristics and possibly PMS symptoms. Therapeutic effects of naltrexone, the orally active opiate antagonist, have been observed in a placebo-controlled, doubleblinded study of PMS patients (Chuong et al., 1988) .
We found no evidence of excessive slowing (ML study) or acceleration (LL study) of LH pulse frequency which might have been predicted if neuroendocrine regulatory mechanisms were dysfunctional. Given the degree of intragroup variability in LH pulse frequency, we were unable to detect small to modest differences in the regulation of GnRI-I secretion in the PMS patients. A true difference of this questionable magnitude seems an unlikely mediator of PMS symptomatology, however, and the pattern of pulsatile LH secretion in PMS patients was similar to that described in previous studies of normal volunteers (Santen & Bardin, 1973; Backstrom et al., 1982; Filicori et al., 1984; Reame et al., 1984) . Taken together, these results provide evidence that the symptoms of PMS can occur in the absence of marked abnormalities in the neuroreproductive axis and challenge the view that opioid inhibition of GnRH secretion is impaired. These findings, however, do not rule out aberrations in other steroid-mediated opioid action external to the hypothalamus that could play a role in the emotional and cognitive symptoms associated with this disorder.
Further studies are necessary to confirm our finding of higher FSH secretion in PMS patients, but it would seem to suggest a lowered sensitivity of FSH to ovarian feedback regulation. Interestingly, this effect was most pronounced during the ML phase, a time when inhibin is believed to act in concert with E 2 to inhibit FSH secretion, and may suggest an area for future study. To what extent a dampening of the ovarian feedback regulation of FSH release might be related to the cyclic psychologic and behavioral disturbances of PMS is purely speculative at present. P secretion, when measured every 30 min in the ML phase, was observed to be pulsatile in PMS patients and similar to that reported for normal women (Filicori et al., 1984) . This finding further strengthens evidence from studies of daily hormone measures that the ability to secrete ovulatory levels of ovarian steroids is not compromised in PMS (Rubinow et al., 1988) . More over, our finding that peripheral plasma P concentrations bear no relationship to PMS symptom severity fails to support the use of ovarian steroids in the treatment of this disorder.
